Assoc. Prof., Dept. of Cell Biology, Scripps Research Institute
Director, UCSD Division of the California Institute for Telecommunications and Information Technology
Co-Founder and Managing Member, Psilos Group
Managing Director, Versant Ventures
Venture Partner at Draper Fisher Jurvetson
President of Global Development, Bill & Melinda Gates Foundation.
CEO, Next Great Place
Professor of Innovation at The University of Texas at Austin
|
|
Fremont, CA-based Ardelyx, which is developing small-molecule drugs to treat gastrointestinal disorders, has raised $17.6 million in Series B funding in a round that could go as high as $22.3 million, according to a regulatory filing last week. Ardelyx’s previous investors include CMEA Capital and New Enterprise Associates (NEA).
San Francisco · 6/3/13
Xconomy offers a number of ways to subscribe for free!
Subscribe Now
